BioSpace News Archive

DUBAI, United Arab Emirates, According to a new analysis from FMI, the Organ Preservation Market is likely to reach US$ 455 Million in revenue by 2032, from US$ 230 Million in 2021, registering a strong robust of 6.4% CAGR during the forecast period.

In 1890 Wilhelm Conrad Roentgen, a German physics professor, presented his lecture titled “Concerning a New Kind of Ray” and introduced X-ray and its application to vast domain of healthcare.

Albany NY, United States: Advanced skin closure systems are rapidly being adopted by patients over the last few years, due to advantages such as minimized scarring and improved tolerance of skin.

Albany NY, United States: A DNA contains all the information required to build and maintain an organism.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors.

United Therapeutics Corporation, a public benefit corporation, announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ in patients with pulmonary arterial hypertension in the journal Pulmonary Circulation.

In a new article appearing in the current issue of the Cell Press scientific journal iScience, AntiCancer Inc. of San Diego has demonstrated that the addiction of cancer to the common amino acid methionine is the basis of the malignancy of cancer.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight i:X® device has successfully received regulatory clearance and is now commercially available to the wound care market in South Korea.

Citius Pharmaceuticals, Inc. reported topline results from the pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Neuro-Bio Ltd, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease.